Cargando…
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
BACKGROUND: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have be...
Autores principales: | Lacquaniti, Antonio, Pasqualetti, Patrizio, Tocco, Teresa Casuscelli di, Campo, Susanna, Rovito, Stefania, Bucca, Maurizio, Ragusa, Antonino, Monardo, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Nephrology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530360/ https://www.ncbi.nlm.nih.gov/pubmed/32839355 http://dx.doi.org/10.23876/j.krcp.20.015 |
Ejemplares similares
-
The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis
por: Lacquaniti, Antonio, et al.
Publicado: (2023) -
Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
por: Rosati, Alberto, et al.
Publicado: (2022) -
Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014) -
Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020) -
Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)